Ra
Rain (Qilu)
Newark CAFounded 201750 employees
Private CapbiotechAcquiredOncology
Platform: Milademetan MDM2
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Daralucimab | RAI-8334 | Phase 2/3 | 2 | FLT3 | SLE | ||
| Rimaratamab | RAI-3417 | Phase 2 | 1 | IL-17A | IgAN |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)